Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10439-022-03112-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancing outcome measure development and analytical approaches: Pain in Animals Workshop 2023.
Front Pain Res (Lausanne)
August 2025
Center for Veterinary Medicine, Food and Drug Administration, Rockville, MD, United States.
Annually, millions of humans and animals suffer from chronic and acute pain, creating welfare and quality of life concerns for both humans and animals who suffer this pain. In developing new therapeutic approaches, the challenge is to accurately measure this pain to ascertain the efficacy of novel therapeutics. Additionally, there is a need to develop new and effective analgesic options that may offer alternatives to using opioids that contribute to the opioid epidemic.
View Article and Find Full Text PDFFDA approves Veozah (Fezolinetant) for menopausal symptoms: a new nonhormonal option.
Ann Med Surg (Lond)
September 2025
Department of Medicine, Georgia State University, Atlanta, USA.
Menopausal vasomotor symptoms (VMS), such as hot flashes and night sweats, significantly impact the quality of life for many women. While hormone therapy remains a standard treatment, it is not suitable for all patients due to contraindications, safety concerns, or personal preferences. Fezolinetant (Veozah), a non-hormonal neurokinin-3 receptor (NK3R) antagonist, has emerged as a novel alternative for managing moderate to severe menopausal VMS.
View Article and Find Full Text PDFReporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines.
JAMA
September 2025
Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
An alternative view of changes in lung function among people with cystic fibrosis.
J Cyst Fibros
September 2025
Department of Medicine, University of Washington, Seattle WA, United States; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle WA, United States; Department of Pediatrics, University of Washington, Seattle WA, United States. Electron
Small cell lung cancer (SCLC): At the door of targeted therapies.
Biomol Biomed
August 2025
College of Medicine, QU Health, Qatar University, Doha, Qatar.
Small-cell lung cancer (SCLC) is a tobacco-associated neuroendocrine tumor comprising ~15% of lung cancers (~150,000 cases/year). For decades, outcomes stagnated: most patients present with extensive-stage disease, screening rarely detects early tumors, surgery is seldom feasible, and platinum-etoposide remained the first-line standard with median overall survival (OS) <12 months. Radiotherapy (including consolidative thoracic RT) and prophylactic cranial irradiation or MRI surveillance offered incremental gains.
View Article and Find Full Text PDF